US › Healthcare

ImmunoPrecise Antibodies Ltd. (HYFT)

US · Healthcare · Biotechnology

$1.31+15.93%

Last close · 2026-09-17

Latest quarter · ended 2026-07-31

Revenue

$3.8M

Revenue YoY

+21.3%

Net profit

$-6.1M

EPS

$-0.09

EPS estimate

$-0.05

Net margin

-158.7%

EPS came in at -0.09 against a street estimate of -0.05 — a miss of 80.0%.

Key statistics

Market cap

$62.5M

Forward P/E

0.0

P/B

7.18

Book value

$0.18

EPS (TTM)

$-0.24

52-week high

$2.99

52-week low

$0.99

50-day MA

$1.38

200-day MA

$1.51

Beta

0.83

Analyst view

with an average price target of $4.33.

Shareholding

Insiders

9.14%

Institutions

9.29%

Largest institutional holders

Fund	Stake
Ingalls & Snyder LLC	6.19%
Susquehanna International Group, LLP	1.14%
Renaissance Technologies Corp	0.49%
XTX Topco Ltd	0.37%
Jane Street Group LLC	0.27%
Bank of Montreal	0.17%
BMO Capital Markets Corp.	0.15%
Bridgeway Capital Management, LLC	0.11%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ImmunoPrecise Antibodies Ltd. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.